Dr. Lal Pathlabs edges ahead on strong quarterly results.

Dr. Lal Pathlabs Ltd. reported its results for the quarter ended June 30, 2017 today. The consolidated numbers were largely strong and higher than the consensus estimates.

The company's total sales for Q4FY17 came in at Rs 249.3 crore, which represents a 13.37 per cent sequential increase and 11.84 per cent YoY increase.

Its operating profit (EBIT) for the quarter amounted to Rs 58.7 crore and its EBIT margin stood at 23.55 per cent.

The company reported PAT of Rs 44.4 crore, which represents a sequential QoQ increase of 40.95 per cent and a YoY increase of 9.9 per cent.
 
Dr. Lal PathLabs Limited is engaged in providing diagnostic and related healthcare tests and services. The company is engaged in the business of running laboratories for carrying out pathological investigations in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, Immunology, virology, cytology, other pathological and radiological investigations

The company's stock opened at Rs 820 on the BSE, rose by 2.3 per cent after the results were declared and closed for the day at Rs.835.